Skip to main content
TLRYTilray Brands, Inc.Hold5.9·$2.53
HoldModerate Confidence
Investment thesis

Tilray is down 89% from its high with 23% revenue growth and 96.8% upside to the analyst target, but it is in a confirmed downtrend, burns cash and sits below the $400M market-cap floor.

Thesis pillars

  • Analyst Target Large Upside→Stable
  • Confirmed Downtrend Capitulation↑Improving
  • Revenue And Earnings Growth→Stable
  • +2 more pillars — see the Why tab for full reasoning

Pillars as of Nov 1, 2026, based on the 10-K filed Jul 28, 2026

Full reasoning →

Open full analysis

Tilray Brands, Inc. (TLRY) Stock Analysis

Falling Knife setup · Inst Constrain edge

HoldVALUE-TRAP 1/5ValueGrowthModerate Confidence

Healthcare · Drug Manufacturers - Specialty & Generic

Hold if already holding. Not a fresh buy at $2.53, but acceptable to hold if already in. Reason: Market cap $374M below $400M minimum.

Tilray Brands operates four segments: Distribution (36% of fiscal 2026 revenue), Cannabis (29%), Beverage (28%) and Wellness (7%). It sells adult-use and medical cannabis in Canada and internationally, craft beer and spirits led by SweetWater, Breckenridge and the newly acquired... Read more

QualityF-score5 / 9FCF yield-4.45%
Stop $2.41Analyst target $4.98(−13% haircut)A.R:R 8.5:1
Analyst consensus$5.72+126.2%9 analysts
$4.98Analyst target
$2.53price
$5.72mean
$13

Hold if already holding. Not a fresh buy at $2.53, but acceptable to hold if already in. Reason: Market cap $374M below $400M minimum. Chart setup: Death cross, below all MAs, RSI 12, MACD bearish. Market cap $374M below $400M minimum. Not in investable universe. Score 5.9/10, moderate confidence.

Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 65d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.

10-K grounded · weekly refresh

About Tilray Brands, Inc.

About Tilray Brands, Inc.

Tilray Brands reported net revenue of $915.5 million for the fiscal year ended May 31, 2026, up from $821.3 million a year earlier, split among Distribution at $327.2 million (36%), Cannabis at $268.3 million (29%), Beverage at $254.0 million (28%) and Wellness at $65.9 million (7%). Headquartered in Leamington, Ontario and New York, the company operates in Canada, the United States, Europe, Australia and Latin America and supplies medical cannabis to patients in over 20 countries.

The Beverage segment ranks as the 4th largest craft brewer in the United States according to the Brewers Association, with brands including SweetWater, Montauk, Breckenridge and Blue Point, and its beverage alcohol products were predominantly sold in the United States during fiscal 2026. Tilray completed the BrewDog acquisition between March and April 2026 to build an international platform and holds a Carlsberg license for U.S. production and distribution starting January 1, 2027. In Cannabis, Canadian adult-use sales were $236.4 million before excise taxes of $84.0 million, and international cannabis revenue reached $84.9 million, helped by EU-GMP facilities in Portugal and Germany and a German distribution network through CC Pharma. The Distribution segment resells pharmaceutical and wellness products, and Wellness centers on Manitoba Harvest hemp foods. In April 2026 the company also acquired UK clinic and digital pharmacy platform Lyphe and holds a 25% interest in a Panamanian medical cannabis venture.

Show full overview

Regulatory change is the clearest swing factor. In April 2026 the U.S. Department of Justice issued an order moving FDA-approved cannabis products and state-licensed medical cannabis from Schedule I to Schedule III, while the DEA conducts an expedited hearing on broader rescheduling that faces challenges in the D.C. Circuit Court of Appeals. Tilray states it expects to be positioned to compete in a federally compliant U.S. market if that path holds. In Canada, each province and territory can separately regulate cannabis distribution, and restrictions on branding, packaging and merchandising may limit how the company differentiates its adult-use brands.

See also: Healthcare · Drug Manufacturers - Specialty & Generic

From Tilray Brands, Inc.'s most recent 10-K filing, extracted October 18, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-11-02
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Jan 7, 202765d to earnings· next earnings call

Thesis

Rewards
No bull case signals
Risks
Market cap $374M below $400M minimum

Key Metrics

P/E (TTM)—
P/E (Fwd)17.8
Mkt Cap$374M
EV/EBITDA40.1
Profit Mgn-17.1%
ROE-9.4%
Rev Growth22.7%
Beta1.92
DividendNone
Rating analysts17

Quality Signals

Piotroski F5/9MoatNarrow

Options Flow

P/C5.97bearish
IV86%elevated

Concentration Risks(10-K Item 1A)

  • MEDIUMGeographicUnited States beverage sales
    10-K Item 1: 'our beverage alcohol products were predominantly sold in the United States'
  • MEDIUMregulatoryCanadian provinces and territories cannabis distribution
    10-K Item 1A: 'each province and territory of Canada has the ability to separately regulate the distribution of cannabis within such province or territory'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers·2 ceiling hits

Unprofitable operations — net margin -17.1%. Quality floor flags this regardless of sector context.static

Roe
0.0
Roa
0.0
Operating Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Gross Margin
1.9
Piotroski F
5.6
Moat
5.8
Current Ratio
6.6
Cash-burning: FCF -2% of revenueQuality concerns

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Obv
1.0
Ma Position
1.0
Rsi
3.0
Macd
3.5
Volume
4.2
Capitulation risk (RSI 12, below 200MA)Volume distribution (falling OBV)Below 200-MA, MA slope -14.5%/30d — confirmed downtrend

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Surprise Avg
0.0
Earnings History
1.1
Erm
5.0
Earnings Timing
5.0
News Activity
8.0
Earnings concerns: 1B/2M
GatesMomentum 2.5<4.5Death cross (50MA < 200MA)A.R:R 8.5 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 65d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARFalling KnifeSuitability: Speculative
RSI
12 · Oversold
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $2.48Resistance $3.84

Price Targets

$2
$5
A.Upside+96.8%
A.R:R8.5:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeSteady

Risk Alerts

! Market cap $374M below $400M minimum
! momentum at 2.5 (below the engine's 4.5 threshold)
! Death cross — 50-day MA below 200-day MA

Earnings

B
M
M
M
1/4 beats
Next Earnings2027-01-07 (65d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is TLRY stock a buy right now?

Hold if already holding. Not a fresh buy at $2.53, but acceptable to hold if already in. Reason: Market cap $374M below $400M minimum. Chart setup: Death cross, below all MAs, RSI 12, MACD bearish. Market cap $374M below $400M minimum. Not in investable universe. Analyst target $4.98 (+96.8%), stop $2.41 (−5.0%), A.R:R 8.5:1. Score 5.9/10, moderate confidence.

What is the TLRY stock price target?

Analyst target: $4.98 (+96.8% upside). Analyst target $4.98 (+96.8%), stop $2.41 (−5.0%), A.R:R 8.5:1. Stop-loss: $2.41.

What are the risks of investing in TLRY?

Market cap $374M below $400M minimum.

Is TLRY overvalued or undervalued?

Tilray Brands, Inc. trades at a P/E of N/A (forward 17.8). TrendMatrix value score: 7.2/10. Verdict: Hold.

What do analysts say about TLRY?

17 analysts cover TLRY with a consensus score of 3.6/5. Average price target: $6.

What does Tilray Brands, Inc. do?Tilray Brands operates four segments: Distribution (36% of fiscal 2026 revenue), Cannabis (29%), Beverage (28%) and...

Tilray Brands operates four segments: Distribution (36% of fiscal 2026 revenue), Cannabis (29%), Beverage (28%) and Wellness (7%). It sells adult-use and medical cannabis in Canada and internationally, craft beer and spirits led by SweetWater, Breckenridge and the newly acquired BrewDog, hemp foods under Manitoba Harvest, and pharmaceutical and wellness products through distribution. Net revenue was $915.5 million for the year ended May 31, 2026.

Related stocks: IRWD (Ironwood Pharmaceuticals, Inc.) · BCRX (BioCryst Pharmaceuticals, Inc.) · ANIP (ANI Pharmaceuticals, Inc.) · CRON (Cronos Group Inc. Common Share) · SUPN (Supernus Pharmaceuticals, Inc.)
Home › Stocks › TLRY

Latest news

Latest News

Fiscal.ai4d ago
Fiscal.ai4d ago
Benzinga4d ago
Fiscal.ai6d ago
Fiscal.ai11d ago
Fiscal.ai12d ago
Benzinga14d agoEarnings
Benzinga20d ago
Benzinga24d agoAnalyst
Benzinga25d agoEarnings
Benzinga25d agoEarnings
Benzinga25d agoEarnings
Benzinga25d ago
Benzinga25d ago
Benzinga25d ago
Benzinga29d agoEarnings
Benzinga34d ago
Benzinga60d agoProduct
Benzinga66d ago
Benzinga74d agoProduct
Loading more...